Literature DB >> 11999623

Visual field constriction and electrophysiological changes associated with vigabatrin.

Dorothea Besch1, Anne Kurtenbach, Eckart Apfelstedt-Sylla, Bettina Sadowski, Dieter Dennig, Christiane Asenbauer, Eberhart Zrenner, Ulrich Schiefer.   

Abstract

PURPOSE: We investigated functional, morphological and electrophysiological changes in patients under anti-epileptic therapy with vigabatrin (VGB), a GABA aminotransferase inhibitor.
METHODS: 20 epileptic patients treated with vigabatrin (age range 25-66 years) were enrolled in this study. The referrals were made by the treating neurologist, based on suspected or known visual field changes in these patients. Two patients had vigabatrin monotherapy, 18 patients were treated with vigabatrin in combination with other antiepileptic drugs. None of the patients reported visual complaints. Patients were examined with psychophysical tests including colour vision (Farnsworth D15), dark adaptation threshold, Goldmann visual fields and Tuebingen Automated Perimetry (90 degrees). A Ganzfeld ERG and an EOG following the ISCEV standard protocol were also obtained. Additionally, all patients were examined with the VERIS multifocal ERG including recordings of multifocal oscillatory potentials.
RESULTS: Visual acuity, anterior and posterior segments, colour vision and dark adaptation thresholds were normal in all patients. Of 20 patients, 18 presented visual field constriction. All patients with visual field defects revealed altered oscillatory potentials waveforms in the ERG, especially in those patients with marked visual field defects. Multifocal oscillatory potentials were also delayed in those patients. In some patients a delayed cone single flash response (6/20), a reduced mERG amplitude (12/20) and a reduced Arden ratio (9/20) were found.
CONCLUSIONS: The present data indicate an effect of vigabatrin on the inner retinal layers. Since abnormalities of the oscillatory potentials were seen in all patients with visual field defects a dysfunction of GABA-ergic retinal cell transmission might be assumed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11999623     DOI: 10.1023/a:1014644307518

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  36 in total

1.  Visual field constriction in children treated with vigabatrin.

Authors:  S Vanhatalo; L Pääkkönen; I Nousiainen
Journal:  Neurology       Date:  1999-05-12       Impact factor: 9.910

2.  Study is needed of visual field defects associated with any long term antiepileptic drug.

Authors:  G P Rao; F A Fat; G Kyle; J P Leach; D W Chadwick; M Batterbury
Journal:  BMJ       Date:  1998-07-18

3.  Severe persistent visual field constriction associated with vigabatrin.

Authors:  T Eke; J F Talbot; M C Lawden
Journal:  BMJ       Date:  1997-01-18

4.  Characteristics of a unique visual field defect attributed to vigabatrin.

Authors:  J M Wild; C Martinez; G Reinshagen; G F Harding
Journal:  Epilepsia       Date:  1999-12       Impact factor: 5.864

5.  Immunocytochemical evidence that vigabatrin in rats causes GABA accumulation in glial cells of the retina.

Authors:  M J Neal; J R Cunningham; M A Shah; S Yazulla
Journal:  Neurosci Lett       Date:  1989-03-13       Impact factor: 3.046

Review 6.  The eclectroretinogram: its components and their origins.

Authors:  K T Brown
Journal:  Vision Res       Date:  1968-06       Impact factor: 1.886

7.  Symptomatic and asymptomatic visual loss in patients taking vigabatrin.

Authors:  H Daneshvar; L Racette; S G Coupland; P J Kertes; A Guberman; D Zackon
Journal:  Ophthalmology       Date:  1999-09       Impact factor: 12.079

8.  No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicenter Group.

Authors:  F Mauguière; P Chauvel; J Dewailly; N Dousse
Journal:  Epilepsia       Date:  1997-03       Impact factor: 5.864

9.  [Disorders of color perception and increase glare sensitivity in phenytoin and carbamazepine therapy. Ocular side effects of anticonvulsants].

Authors:  A Bayer; H J Thiel; E Zrenner; W Paulus; S Ried; D Schmidt
Journal:  Nervenarzt       Date:  1995-02       Impact factor: 1.214

10.  A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort.

Authors:  J A French; M Mosier; S Walker; K Sommerville; N Sussman
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

View more
  13 in total

1.  The effect of GABA and the GABA-uptake-blocker NO-711 on the b-wave of the ERG and the responses of horizontal cells to light.

Authors:  Renate Hanitzsch; Lea Küppers; Andreas Flade
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09       Impact factor: 3.117

2.  Electroretinographic (ERG) responses in pediatric patients using vigabatrin.

Authors:  Anne Moskowitz; Ronald M Hansen; Susan E Eklund; Anne B Fulton
Journal:  Doc Ophthalmol       Date:  2012-03-20       Impact factor: 2.379

3.  Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?

Authors:  Bláthnaid McCoy; Thomas Wright; Shelly Weiss; Cristina Go; Carol A Westall
Journal:  J Child Neurol       Date:  2011-02-22       Impact factor: 1.987

4.  Reduced visual function associated with infantile spasms in children on vigabatrin therapy.

Authors:  Dena S Hammoudi; Sophia S F Lee; Adena Madison; Giuseppe Mirabella; J Raymond Buncic; William J Logan; O Carter Snead; Carol A Westall
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-02       Impact factor: 4.799

5.  Modelling the topography of absolute defects in patients exposed to the anti-epileptic drug vigabatrin and in normal subjects using automated static suprathreshold perimetry of the entire 80° visual field.

Authors:  Dorothea Besch; Ulrich Schiefer; Nicole Eter; Roland Burth; Christian E Elger; Manfred Spitznas; Klaus Dietz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-05       Impact factor: 3.117

Review 6.  The safety and tolerability of newer antiepileptic drugs in children and adolescents.

Authors:  Dean P Sarco; Blaise F D Bourgeois
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

Review 7.  CNS adverse events associated with antiepileptic drugs.

Authors:  Gina M Kennedy; Samden D Lhatoo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.

Authors:  John M Wild; Catherine Chiron; Hyosook Ahn; Michel Baulac; Joseph Bursztyn; Enrico Gandolfo; Ivan Goldberg; Francisco Javier Goñi; Florence Mercier; Jean-Philippe Nordmann; Avinoam B Safran; Ulrich Schiefer; Emilio Perucca
Journal:  CNS Drugs       Date:  2009-11       Impact factor: 5.749

9.  Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children.

Authors:  J Raymond Buncic; Carol A Westall; Carole M Panton; J Robert Munn; Leslie D MacKeen; William J Logan
Journal:  Ophthalmology       Date:  2004-10       Impact factor: 12.079

10.  Changes in the electroretinogram resulting from discontinuation of vigabatrin in children.

Authors:  Carol A Westall; Rita Nobile; Sharon Morong; J Raymond Buncic; William J Logan; Carole M Panton
Journal:  Doc Ophthalmol       Date:  2003-11       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.